First Time Loading...

BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 5.3095 USD 3.1%
Updated: Mar 28, 2024

Intrinsic Value

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. [ Read More ]

The intrinsic value of one BCRX stock under the Base Case scenario is 12.9296 USD. Compared to the current market price of 5.3095 USD, BioCryst Pharmaceuticals Inc is Undervalued by 59%.

Key Points:
BCRX Intrinsic Value
Base Case
12.9296 USD
Undervaluation 59%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
BioCryst Pharmaceuticals Inc

Backtest BCRX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BCRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of BioCryst Pharmaceuticals Inc's business.

What risks and challenges
does BioCryst Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of BioCryst Pharmaceuticals Inc.

Provide P/E
for BioCryst Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
BioCryst Pharmaceuticals Inc

Current Assets 496m
Cash & Short-Term Investments 389m
Receivables 57m
Other Current Assets 50m
Non-Current Assets 21m
PP&E 20.9m
Other Non-Current Assets 80k
Current Liabilities 150m
Accounts Payable 20.9m
Accrued Liabilities 103.9m
Other Current Liabilities 25.2m
Non-Current Liabilities 822.5m
Long-Term Debt 814.1m
Other Non-Current Liabilities 8.4m
Efficiency

Earnings Waterfall
BioCryst Pharmaceuticals Inc

Revenue
331.4m USD
Cost of Revenue
-4.7m USD
Gross Profit
326.8m USD
Operating Expenses
-428.9m USD
Operating Income
-102.2m USD
Other Expenses
-124.4m USD
Net Income
-226.5m USD

Free Cash Flow Analysis
BioCryst Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

BCRX Profitability Score
Profitability Due Diligence

BioCryst Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional ROE
53/100
Profitability
Score

BioCryst Pharmaceuticals Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

BCRX Solvency Score
Solvency Due Diligence

BioCryst Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
37/100
Solvency
Score

BioCryst Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc

Wall Street analysts forecast BCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCRX is 14.0946 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.

Lowest
Price Target
6.06 USD
14% Upside
Average
Price Target
14.0946 USD
165% Upside
Highest
Price Target
31.5 USD
493% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BCRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BCRX Price
BioCryst Pharmaceuticals Inc

1M 1M
-7%
6M 6M
-27%
1Y 1Y
-38%
3Y 3Y
-45%
5Y 5Y
-33%
10Y 10Y
-48%
Annual Price Range
5.3095
52w Low
4.89
52w High
8.81
Price Metrics
Average Annual Return 33.03%
Standard Deviation of Annual Returns 83.96%
Max Drawdown -83%
Shares Statistics
Market Capitalization 1.1B USD
Shares Outstanding 206 150 000
Percentage of Shares Shorted 15.69%

BCRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.1B USD

Dividend Yield

0%

Description

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

Contact

NORTH CAROLINA
Durham
4505 Emperor Blvd Ste 200
+19198591302.0
https://www.biocryst.com/

IPO

1994-03-04

Employees

358

Officers

CEO, President & Executive Director
Mr. Jon P. Stonehouse
Senior VP & CFO
Mr. Anthony J. Doyle
Senior VP, Chief Legal Officer & Corporate Secretary
Ms. Alane P. Barnes
Chief Development Officer
Dr. William P. Sheridan MBBS
Chief Discovery Officer
Dr. Yarlagadda S. Babu
Chief Research & Development Officer
Dr. Helen M. Thackray FAAP, M.D.
Show More
Senior VP & Chief Commercial Officer
Mr. Charles K. Gayer
Executive Director of Finance & Principal Accounting Officer
Mr. Michael L. Jones
Chief Communications Officer
Mr. John D. Bluth
Chief People Officer
Ms. Stephanie Angelini
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCRX stock?

The intrinsic value of one BCRX stock under the Base Case scenario is 12.9296 USD.

Is BCRX stock undervalued or overvalued?

Compared to the current market price of 5.3095 USD, BioCryst Pharmaceuticals Inc is Undervalued by 59%.